The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

By sjmartinez • November 26, 2022

Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clin Res Rep. 2022 Oct 29;3(12):100427. doi: 10.1016/j.jtocrr.2022.100427. PMID: 36426286; PMCID: PMC9679033.

Tags: Actionable mutations, chemotherapy, Driver mutations, General Internal Medicine, immune checkpoint inhibitors, Non–small cell lung cancer, Oncogenic driven, Publications

Evaluating selected gene therapies for cardiovascular diseases: an updated scoping review and evidence map of randomised controlled trials

Apaydin EA, Richard J, Miner SA, Waymouth M, Roberts D, Vockley J, Richardson AS. Evaluating selected gene therapies for cardiovascular diseases: an updated scoping review[...]

Primary intestinal lymphangiectasia across the lifespan: adult-pediatric comparisons of diagnostic delay, immune findings, and treatment patterns

Stirrat T, Solanky P, Thiru S, Singh L, Mehta S, Kanth P. Primary intestinal lymphangiectasia across the lifespan: adult-pediatric comparisons of diagnostic delay, immune findings,[...]

Interdisciplinary Weight Management in a Safety-Net Health System: A Pilot Implementation Study

DeCan C, Thure K, Pedley N, Cervantes B, Camargo O, Fing Castro K, Cabral J, Gallardo M, Rodriguez Reyes D, Perez A, Young S, Nafisi[...]